iBio, Inc. (IBIO): Price and Financial Metrics


iBio, Inc. (IBIO): $0.74

0.02 (+2.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IBIO POWR Grades

  • Value is the dimension where IBIO ranks best; there it ranks ahead of 42.41% of US stocks.
  • IBIO's strongest trending metric is Sentiment; it's been moving up over the last 106 days.
  • IBIO's current lowest rank is in the Quality metric (where it is better than 0.62% of US stocks).

IBIO Stock Summary

  • With a market capitalization of $6,471,923, IBIO INC has a greater market value than merely 1.63% of US stocks.
  • The volatility of IBIO INC's share price is greater than that of 98.48% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IBIO comes in at 74.88% -- higher than that of 97.65% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IBIO INC are EMKR, SCWX, PEAR, LAW, and DZSI.
  • IBIO's SEC filings can be seen here. And to visit IBIO INC's official web site, go to www.ibioinc.com.

IBIO Valuation Summary

  • In comparison to the median Healthcare stock, IBIO's price/earnings ratio is 100.44% lower, now standing at -0.1.
  • Over the past 160 months, IBIO's price/earnings ratio has gone up 9.4.

Below are key valuation metrics over time for IBIO.

Stock Date P/S P/B P/E EV/EBIT
IBIO 2023-01-20 2.9 0.1 -0.1 -0.3
IBIO 2023-01-19 2.9 0.1 -0.1 -0.3
IBIO 2023-01-18 2.9 0.1 -0.1 -0.3
IBIO 2023-01-17 3.0 0.1 -0.1 -0.3
IBIO 2023-01-13 3.5 0.2 -0.1 -0.3
IBIO 2023-01-12 3.1 0.1 -0.1 -0.3

IBIO Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 339.39%.
  • Its 4 year net income to common stockholders growth rate is now at -203.93%.
  • Its 4 year revenue growth rate is now at 151.53%.
IBIO's revenue has moved up $1,650,000 over the prior 67 months.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.172 -42.092 -59.516
2022-06-30 2.383 -37.48 -50.391
2022-03-31 2.813 -33.203 -33.286
2021-12-31 1.635 -34.608 -28.621
2021-09-30 2.172 -32.341 -24.873
2021-06-30 2.371 -30.064 -23.467

IBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
  • IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
  • COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.

The table below shows IBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.383 -0.256
2021-03-31 0.024 0.836 -0.331
2020-12-31 0.023 1.000 -0.317
2020-09-30 0.027 1.000 -0.273
2020-06-30 0.032 1.000 -0.231
2020-03-31 0.036 1.000 -0.271

IBIO Stock Price Chart Interactive Chart >

Price chart for IBIO

IBIO Price/Volume Stats

Current price $0.74 52-week high $16.51
Prev. close $0.72 52-week low $0.36
Day low $0.70 Volume 188,100
Day high $0.74 Avg. volume 891,006
50-day MA $0.90 Dividend yield N/A
200-day MA $4.76 Market Cap 6.66M

iBio, Inc. (IBIO) Company Bio


iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.


IBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream


Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio Announces Closing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock, at a combine

Yahoo | December 9, 2022

7 Penny Stocks to Sell Before They Plunge in 2023

These penny stocks to sell have been incredibly volatile this year and should be discarded from your portfolios heading into 2023

Muslim Farooque on InvestorPlace | December 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday!

William White on InvestorPlace | December 7, 2022

25 Penny Stocks to Sell Before They Die

Wondering which small-cap companies you should offload before 2023?

Samuel O'Brient on InvestorPlace | December 7, 2022

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,365,385 shares of common stock and Series B warrants to purchase up to 3,365,385 shares of common stock, at a combine

Yahoo | December 7, 2022

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo 64.81%
3-mo -64.76%
6-mo -87.25%
1-year -93.35%
3-year -87.87%
5-year -98.36%
YTD 66.52%
2022 -96.76%
2021 -47.71%
2020 321.69%
2019 -66.80%
2018 -57.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5655 seconds.